Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade

Thyrotoxicosis is a common immune-related adverse event in patients treated with programmed cell death protein-1 (PD1) or programmed cell death protein ligand-1 (PD-L1) blockade. A detailed endocrinological assessment, including thyroid ultrasound and scintigraphy, is lacking, as are data on response to treatment and follow-up.The aim of this study was to better characterize the thyrotoxicosis secondary to immune checkpoint inhibitors, gaining...